Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial

Main Article Content

Brittany Craiglow
Yale University, New Haven, USA

Lisa Arkin
University of Wisconsin, Madison, USA

David Saceda-Corralo
University Hospital Ramón y Cajal, Madrid & Dermatology Group Pedro Jaén, Madrid, Spain

Young Lee
Chungnam National University, Daejeon, Korea

Manabu Ohyama
Kyorin University, Tokyo, Japan

Yves Dutronc
Eli Lilly and Company, Indianapolis, USA

Stephanie Colvin
Eli Lilly and Company, Indianapolis, USA

Karen Denning
Eli Lilly and Company, Indianapolis, USA

Sylvia Su
Eli Lilly and Company, Indianapolis, USA

Tuhina Das
Eli Lilly and Company, Indianapolis, USA

Ulrike Blume-Peytavi
Charité-Universitätsmedizin, Berlin, Germany

Keywords

Alopecia Areata

References

1. Villasante Fricke AC and Miteva M. Clin Cosmet Investig Dermatol. 2015;8:397-403.

2. Tan IJ and Jafferany M. J Paediatr Child Health. 2024;60:778-782.

3. Senna M, et al. J Eur Acad Dermatol Venereol. 2024;38:583-593.

4. Passeron T, et al. Oral presentation at: AAD25. Presentation number S040.

5. Torrelo A, et al. Br J Dermatol. 2023;189:23-32.

6. King B, et al. Br J Dermatol. 2023;188:218-227

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/rw150t68

Article Details

How to Cite
1.
Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial. J of Skin. 2025;9(6):s666. doi:10.25251/rw150t68
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Alopecia
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>